Machine Learning for Population PK Model Selection: Theory and Practice On-Demand Webinar 机器学习在群体药代动力学模型选择中的应用:理论与实践 Three of Certara's expert modelers provide a gentle introduction to machine learning in our field.…Danielle Pillsbury2025 年 2 月 7 日
Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling On-Demand Webinar Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling With the release of Version 24, the Simcyp Simulator introduces cutting-edge enhancements that further elevate…Danielle Pillsbury2025 年 2 月 7 日
Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies Publication 针对复发难治性(R/R)骨髓纤维化(MF)及其他髓系或实体瘤恶性肿瘤患者的 Navtemadlin 群体药代动力学与药效学分析 This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…Danielle Pillsbury2025 年 2 月 6 日
Understanding Variability in CAR-T Cell Therapy Kinetics Publication 了解 CAR-T 细胞疗法动力学的变异性 Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…Danielle Pillsbury2025 年 1 月 23 日
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA) On-Demand Webinar 利用基于模型的荟萃分析 (MBMA) 解决药物开发难题 In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…Danielle Pillsbury2025 年 1 月 9 日
Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA Poster 临床前数据暴露无法预测双特异性 T 细胞吸引剂在实体瘤适应症中的临床生理活性剂量;是否有更好的衡量标准?— 来自小型机制性 MBMA 的启示 Danielle Pillsbury2024 年 12 月 11 日
Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development Video Piet van der Graaf 谈人工智能和人工智能辅助药物研发方法 At the 2024 AAPS PharmSci 360 conference, Bioanalysis Zone interviewed Piet van der Graaf, Senior…Danielle Pillsbury2024 年 12 月 10 日
Advancing pharmacometrics in Africa – Transition from capacity development toward job creation Publication 推动非洲定量药理学的发展 — 从能力建设向创造就业过渡 This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…Danielle Pillsbury2024 年 12 月 9 日
Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi Poster GalNAc-siRNA 偶联物 Plozasiran(ARO-APOC3)治疗严重高甘油三酯血症患者的群体药代动力学-药效学(K-PD)建模 Danielle Pillsbury2024 年 11 月 22 日
健康受试者中TBA-7371的群体药代动力学建模揭示了清除率的表观自身诱导现象,并预测了结核分枝杆菌感染受试者的药代动力学 海报 健康受试者中TBA-7371的群体药代动力学建模揭示了清除率的表观自身诱导现象,并预测了结核分枝杆菌感染受试者的药代动力学 Danielle Pillsbury2024 年 11 月 22 日